Full Text
PCN7 THE LIFETIME COST OF GEFITINIB ('IRESSA') IN TREATING PATIENTS WITH NON-SMALL-CELL LUNG CANCER (NSCLC)

Abstract

Authors

A Haiderali W Chin

Back to Volume 7, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×